CytRx Corp (CYTR) Commences Adoxorubicin Phase 1b in Advanced Solid Tumors
Tweet Send to a Friend
CytRx Corporation (Nasdaq: CYTR), has initiated a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
